Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE study of high-dose intravenous Monofer in inflammatory bowel disease-related iron deficiency anemia
NL-OMON38924Recruiting
- Sponsor
- Pharmacosmos
- Start
- Feb 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Adverse drug reactions. Started Feb 2014; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON38924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38924.